Efficacy and safety of cariprazine in the treatment of bipolar disorder

References

• Merikangas KR, Jin R, He J, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2012;68:241–251.
   Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007;64:543.
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J Affect Disord. 2004;81:123–131.
   PubMed Web of Science ®Google Scholar
• Gignac A, McGirr A, Lam RW, et al. Course and outcome following a first episode of mania: four-year prospective data from the systematic treatment optimization program (STOP-EM). J Affect Disord. 2015;175:411–417.
   PubMed Web of Science ®Google Scholar
• Gignac A, McGirr A, Lam RW, et al. Recovery and recurrence following a first episode of mania: a systematic review and meta-analysis of prospectively characterized cohorts. J Clin Psychiatry. 2015;76:1241–1248.
   PubMed Web of Science ®Google Scholar
• Keller MB, Lavori PW, Coryell W, et al. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis. 1993;181:238–245.
   PubMed Web of Science ®Google Scholar
• Bromet EJ, Finch SJ, Carlson GA, et al. Time to remission and relapse after the first hospital admission in severe bipolar disorder. Soc Psychiatry Psychiatr Epidemiol. 2005;40:106–113.
   PubMed Web of Science ®Google Scholar
• Tohen M, Zarate CA, Hennen J, et al. The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160:2099–2107.
   PubMed Web of Science ®Google Scholar
• Gitlin MJ, Swendsen J, Heller TL, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152:1635–1640.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and {II} Disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62:1322–1330.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–537.
   PubMed Web of Science ®Google Scholar
• Parikh SV, Hawke LD, Velyvis V, et al. Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disord. 2015;17:86–96.
   PubMed Web of Science ®Google Scholar
• Forte A, Baldessarini RJ, Tondo L, et al. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015;178:71–78.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry. 2006;163:217–224.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Gonda X, Vieta E, et al. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis. Ann Gen Psychiatry. 2009;8:27.
   PubMedGoogle Scholar
• Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand. 2007;116:17–26.
   PubMed Web of Science ®Google Scholar
• Solé B, Jiménez E, Torrent C, et al. Cognitive impairment in bipolar disorder: treatment and prevention strategies. Int J Neuropsychopharmacol. 2017;20:670–680.
   PubMed Web of Science ®Google Scholar
• Bond DJ, Kauer-Sant’Anna M, Lam RW, et al. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the systematic treatment optimization program for early mania (STOP-EM). J Affect Disord. 2010;124:108–117.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170:265–274.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.
   PubMed Web of Science ®Google Scholar
• Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017;20:788–796.
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Lasoń-Tyburkiewicz M, et al. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25:567–574.
   PubMed Web of Science ®Google Scholar
• Barnes SA, Young JW, Markou A, et al. The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task. Psychopharmacology (Berl). 2018;235:1403–1414.
   PubMed Web of Science ®Google Scholar
• Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375–389.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Approval package for 21-436/S-005 & S-008 & 21-713/S-003. Rockville, Maryland; 2005.
   Google Scholar
• Otsuka Pharmaceutical Co. Ltd. REXULTI® (brexpiprazole) tablets, for oral use: US prescribing information; 2015.
   Google Scholar
• Pompili M, Verzura C, Trovini G, et al. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders. Expert Opin Drug Saf. 2018;17:197–205.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Pikalov A, Streicher C, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017;27:865–876.
   PubMed Web of Science ®Google Scholar
• Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328–340.
   PubMed Web of Science ®Google Scholar
• Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl). 2005;179:567–575.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Di Cara B, Dekeyne A, et al. Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem. 2007;100:1047–1061.
   PubMed Web of Science ®Google Scholar
• Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59:925–935.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21:123–127.
   PubMed Web of Science ®Google Scholar
• Román V, Gyertyán I, Sághy K, et al. Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. Psychopharmacology (Berl). 2013;226:285–293.
   PubMed Web of Science ®Google Scholar
• Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. In: Meyer M, Gross G, editors. Novel Schizophrenia treatments, Handbook of Experimental Pharmacology. Vol. 213.Berlin, Heidelberg: Springer; 2012p. 167–210.
   Google Scholar
• Agai-Csongor E, Domány G, Nógrádi K, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012;22:3437–3440.
   PubMed Web of Science ®Google Scholar
• US FDA. VraylarTM (cariprazine): US prescribing information; 2015.
   Google Scholar
• US FDA. Vraylar TM (Cariprazine): US prescribing information; 2019.
   Google Scholar
• Deák K, Takács-Novák K, Kapás M, et al. Physico-chemical characterization of a novel group of dopamine D(3)/D(2) receptor ligands, potential atypical antipsychotic agents. J Pharm Biomed Anal. 2008;48:678–684.
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Diaz J, Foll BL, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006;5:25–43.
   PubMedGoogle Scholar
• Laszlovszky I, N´emeth G, P´asztor M´esz´aros G, et al. P.3.c.053 dopamine D2/D3 receptor occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic, in healthy volunteers. Eur Neuropsychopharmacol. 2007;17:S455.
   Web of Science ®Google Scholar
• Girgis RR, Slifstein M, D’Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology (Berl). 2016;233:3503–3512.
   PubMed Web of Science ®Google Scholar
• Keator DB, Mukherjee J, Preda A, et al. Dopamine D2 and. D3 receptor occupancy of cariprazine in schizophrenic patients. Schizophr Bull. 2009;35:154.
   Web of Science ®Google Scholar
• Potkin S, Keator D, Mukherjee J, et al. P.1.e.028 dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol. 2009;19:S316.
   Web of Science ®Google Scholar
• Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53:193–203.
   PubMed Web of Science ®Google Scholar
• Bantick RA, Deakin JFW, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol. 2001;15:37–46.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, Nemeroff CB. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 5th ed. Arlington, VA: The American Psychiatric Association Publishing; 2017. Chapter 34, Cariprazine; p. 831–853.
   Google Scholar
• Citrome L, Durgam S, Lu K, et al. The effect of cariprazine on hostility associated with schizophrenia. J Clin Psychiatry. 2016;77:109–115.
   PubMed Web of Science ®Google Scholar
• Actavis Pharma I VraylarTM (cariprazine) capsules: US prescribing information [Internet]. 2017. [cited Aug 23]. Available from: http://www.allergan.com.
   Google Scholar
• Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol. 2011;7:829–846.
   PubMed Web of Science ®Google Scholar
• Caccia S, Invernizzi RW, Nobili A, et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319–328.
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;193–206.
   PubMed Web of Science ®Google Scholar
• Spina E, Italiano D. Mood stabilizers. In: Jann MW, Penzak SR, Cohen LJ, editors. Applied clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents. Switzerland: Springer International Publishing; 2016. p. 177–203.
   Google Scholar
• McCormack PL. Cariprazine: first global approval. Drugs. 2015;75:2035–2043.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327–338.
   PubMed Web of Science ®Google Scholar
• Citrome L. The ABC’s of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69:1211–1220.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s essential psychopharmacology: the prescribers guide. 5th ed. New York (NY): Cambridge University Press; 2014.
   Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164–172.
   PubMed Web of Science ®Google Scholar
• González-Pinto A, Reed C, Novick D, et al. Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry. 2010;43:263–270.
   PubMed Web of Science ®Google Scholar
• Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17:63–75.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296–302.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck, Jr PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder. J Clin Psychiatry. 2015;76:284–292.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Sachs GS, Durgam S, et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord. 2018;225:350–356.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173:271–281.
   PubMed Web of Science ®Google Scholar
• Earley W, Victoria Burgess M, Rekeda L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019 appi.ajp.2018.1;176:439–448.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Vieta E, Earley W. Evaluation of cariprazine in the treatment of bipolar I and II depression: A randomized, double-blind, placebo-controlled phase II trial. Int Clin Psychopharmacol. 2019; In revision.
   Google Scholar
• Earley W, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar I depression: A double blind, placebo-controlled phase III study. Bipolar Disord. 2019; In press.
   PubMed Web of Science ®Google Scholar
• Earley W, Durgam S, Lu K, et al. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018;226:239–244.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Torres IJ, Malhi GS, et al. The International Society for Bipolar Disorders Battery for Assessment of Neurocognition. Bipolar Disord. 2010;12:351–363.
   Web of Science ®Google Scholar